Novo Nordisk hopes that its attempt to preserve beta cells will fare better than Caladrius’s, while Aslan tries its hand at DHODH inhibition.
Shares in the company surge after its weekly growth hormone treatment proves superior to daily injections, raising broader hopes for Ascendis’s long-acting technology.
Lilly's authorised Humalog generic price undercuts Sanofi’s copycat attack, but will cut into branded sales.
Climbing consensus sales forecasts for 2022 suggest that last year equity analysts brushed off concerns about pricing restraints.
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
A capsule device inspired by the shape of a tortoise’s shell might just be able to deliver proteins orally, and Novo Nordisk is on board. But the tech is still years away…
Biopharma companies put the brakes on product deals last year, with the drop driven by a decline in oncology transactions. Meanwhile, a look at the big spenders shows how…
Pfizer is said to be interested in Amarin, but the Danish group’s need for a growth injection is greater.
As the curtain came down on a quarter many in biotech would rather forget, big pharma groups stood out by being the least bad investment option.